PMID- 7790112
OWN - NLM
STAT- MEDLINE
DCOM- 19950725
LR  - 20190708
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 61
IP  - 6
DP  - 1995 Jun 9
TI  - Substance-P receptors in human primary neoplasms: tumoral and vascular 
      localization.
PG  - 786-92
AB  - Primary human neoplasms were examined for the presence of substance-P receptors 
      by receptor autoradiography with 125I-labelled Bolton-Hunter substance P. 
      Substance-P receptors were localized and characterized in the neoplastic cells of 
      9/12 astrocytomas, 10/10 glioblastomas, 10/12 medullary thyroid carcinomas, 8/16 
      breast carcinomas and 4/5 ganglioneuroblastomas. Conversely, substance-P 
      receptors were not or only rarely identified on non-small-cell carcinomas of the 
      lung (1/16), neuroblastomas (0/8), adenocarcinomas of the colon (1/21) or the 
      pancreas (1/9), or on malignant lymphomas (3/18). However, in the great majority 
      of the investigated tumours, substance-P receptors were found on intra- and 
      peritumoral blood vessels. All substance-P receptors detected had the 
      pharmacological characteristics of the neurokinin-I receptor sub-type. In 
      addition, the expression of somatostatin receptors was examined in all the 
      neoplastic tissues mentioned above. Both substance-P and somatostatin receptors 
      were present in astrocytomas and in ganglioneuroblastomas, whereas little or no 
      receptor was found in pancreatic and non-small-cell lung carcinomas. The extent 
      of somatostatin-receptor expression was inversely correlated to that of the 
      substance-P receptors in glioblastomas, neuroblastomas and non-Hodgkin's 
      lymphomas. The tumoral and vascular localization of substance-P receptors in 
      tumours may have clinical implications. The use of radiolabelled substance P for 
      in vivo scintigraphy may supplement the current set of diagnostic tools. 
      Substance-P antagonists might be used in the treatment of tumours, as their 
      binding to vascular receptors may decrease tumoral blood supply and drainage.
FAU - Hennig, I M
AU  - Hennig IM
AD  - Division of Cell Biology and Experimental Cancer Research, University of Berne, 
      Switzerland.
FAU - Laissue, J A
AU  - Laissue JA
FAU - Horisberger, U
AU  - Horisberger U
FAU - Reubi, J C
AU  - Reubi JC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Receptors, Neurokinin-1)
RN  - 0 (Receptors, Somatostatin)
SB  - IM
MH  - Autoradiography
MH  - Blood Vessels/chemistry
MH  - Humans
MH  - Neoplasms/blood supply/*chemistry/pathology
MH  - Radioligand Assay
MH  - Receptors, Neurokinin-1/*analysis
MH  - Receptors, Somatostatin/analysis
EDAT- 1995/06/09 00:00
MHDA- 1995/06/09 00:01
CRDT- 1995/06/09 00:00
PHST- 1995/06/09 00:00 [pubmed]
PHST- 1995/06/09 00:01 [medline]
PHST- 1995/06/09 00:00 [entrez]
AID - 10.1002/ijc.2910610608 [doi]
PST - ppublish
SO  - Int J Cancer. 1995 Jun 9;61(6):786-92. doi: 10.1002/ijc.2910610608.